FOURIER analyses show benefit of evolocumab for PAD and MI
American College of Cardiology News Nov 21, 2017
PCSK9 inhibition with evolocumab significantly reduced the risk of cardiovascular events in patients with peripheral artery disease (PAD), according to an analysis of the FOURIER trial presented November 13, at American Heart Association (AHA) Scientific Sessions 2017, and simultaneously published in the journal Circulation. A separate analysis also showed the benefit of evolocumab in patients with a history of myocardial infarction (MI).
Marc P. Bonaca, MD, MPH, looked at 3,642 patients with PAD in the FOURIER trial. Results showed that evolocumab significantly reduced the primary endpointÂa composite of cardiovascular death, MI, stroke, hospital admission for unstable angina, or coronary revascularizationÂin these patients. Further, evolocumab reduced the risk of major adverse limb events in all patients with consistent effects in those with and without known PAD.
In a separate FOURIER trial analysis that looked at 22,351 patients with a history of MI, Marc S. Sabatine, MD, MPH, FACC, et al., found that patients closer to their most recent MI, with multiple prior MIs, or with residual multivessel coronary artery disease were at a 34-90% greater risk for major vascular events.
In addition, these patients experience substantial relative risk reductions (21-30%) and absolute risk reductions (2.6-3.4% over three years) with intensive LDL-C lowering with the PCSK9 inhibitor evolocumab.
The researchers conclude that a patient's history of coronary disease offers a way to tailor PCSK9 inhibitor use to maximize benefit.
Go to Original
Marc P. Bonaca, MD, MPH, looked at 3,642 patients with PAD in the FOURIER trial. Results showed that evolocumab significantly reduced the primary endpointÂa composite of cardiovascular death, MI, stroke, hospital admission for unstable angina, or coronary revascularizationÂin these patients. Further, evolocumab reduced the risk of major adverse limb events in all patients with consistent effects in those with and without known PAD.
In a separate FOURIER trial analysis that looked at 22,351 patients with a history of MI, Marc S. Sabatine, MD, MPH, FACC, et al., found that patients closer to their most recent MI, with multiple prior MIs, or with residual multivessel coronary artery disease were at a 34-90% greater risk for major vascular events.
In addition, these patients experience substantial relative risk reductions (21-30%) and absolute risk reductions (2.6-3.4% over three years) with intensive LDL-C lowering with the PCSK9 inhibitor evolocumab.
The researchers conclude that a patient's history of coronary disease offers a way to tailor PCSK9 inhibitor use to maximize benefit.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
